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A mitochondrial matrix copper ligand
(CuL) complex, conserved in
mammalian cells, is shown for the first
time to be the source of copper for
cytochrome c oxidase (CcO) and
superoxide dismutase-1 (Sod1) within the
intermembrane space (IMS) in yeast.
Targeting the copper-binding proteins,
human Sod1 and Crs5, to the
mitochondrial matrix results in growth
impairment on non-fermentable medium
due to decreased levels of CcO. This
effect is reversed by copper
supplementation. Matrix-targeted Crs5
diminished Sod1 protein within the IMS
and impaired activity of an inner
membrane tethered hSod1. Copper
binding by the matrix-targeted proteins
attenuates levels of the CuL complex
without affecting total mitochondrial
copper. These data suggest that
attenuation of the matrix CuL complex
via heterologous competitors limits
available copper for metallation of CcO
and Sod1 within the IMS. The ligand
also exists in the cytoplasm in an
apparent metal-free state.
Copper is required within the
mitochondrion for assembly of cytochrome
c oxidase (CcO) and superoxide dismutase
(Sod1) (1,2). The copper-binding subunits
of CcO are encoded by the mitochondrial
genome, so copper insertion into CcO
occurs within the organelle. Cox17
functions in Cu(I) delivery within the
mitochondrial intermembrane space (IMS)
to two accessory proteins, Sco1 and Cox11,
for the subsequent copper insertion into
CcO (3). Approximately 1-5% of total
Sod1 is also localized within the IMS and
its localization within this compartment is
dependent on Ccs1 (2). Mitochondrial Sod1
is imported as a metal-free polypeptide, so
its activation occurs within the IMS by
Ccs1 (4). The presence of two copper
metalloenzymes that are metallated within
the mitochondrion necessitates a specific
copper transport pathway to the IMS.
Copper ions enter
Saccharomyces cerevisiae cells through
a combination of high affinity (Ctr1 and
Ctr3) and low affinity (Fet4 and Smf1)
permeases (5). Within the cytoplasm
copper levels are buffered by two
metallothioneins  (Cup1 and Crs5), that
limit the free aqueous copper pool (6).
Copper ions are shuttled to sites of
utilization by protein-mediated transfer
using proteins designated
metallochaperones which include Atx1
and Ccs1 (7,8). Atx1 shuttles Cu(I) to
the Ccc2 P-type ATPase transporter
localized in post-Golgi vesicles for
incorporation into the plasma membrane
iron permease ferroxidase, Fet3 (9).
Ccs1 provides Cu(I) for activation of
Sod1 and also catalyzes the formation of
an essential disulfide bond in Sod1 (10).
Yeast lacking Ccs1 fail to activate Sod1
and have oxygen-dependent phenotypes.
2One unknown aspect is how these
proteins acquire copper prior to delivery
to utilization sites. Metallochaperone
function is not impaired in cells lacking
the high and low affinity transporters
(Ctr1, Ctr3 and Fet4) in replete medium
suggesting that the chaperones are not
intrinsically dependent on any
interaction with these transporters (11).
Cytoplasmic copper ion delivery to
Sod1 and Ccc2 is protein-mediated (12).
The presence of Ccs1 and Cox17 in both
the cytoplasm and IMS made them
candidates for shuttling copper ions to the
mitochondrion for subsequent functions
(13). However, yeast lacking either Ccs1 or
Cox17 retain wild type mitochondrial
copper levels (14). In addition, tethering
Cox17 to the mitochondrial inner
membrane by a heterologous membrane-
binding domain resulted in its exclusive
localization within the organelle, and CcO
assembly proceeded normally (15).  Thus,
Cox17 and Ccs1 cannot be obligate
mitochondrial copper transporting
metallochaperones. The metallochaperone
paradigm predicts that translocation of
Cu(I) to the mitochondrion is mediated by
another metallochaperone or transport
pathway.
Copper is utilized in the
metallation of CcO and Sod1 within the
IMS, yet the most substantial pool of
mitochondrial copper is localized within
the matrix (14). The matrix copper pool
is present as a soluble, low molecular
weight, non-proteinaceous copper-
complex (14). Here we show that this
copper-complex is conserved in yeast
and mouse and that targeting of
heterologous copper-binding proteins to
the matrix attenuates the activation of
both CcO and Sod1 within the IMS. In
addition we present data suggesting that
the ligand from this copper-complex is
found in the cytoplasm where it may
recruit, in place of a metallochaperone,
the copper that is translocated and stored
within the mitochondrial matrix for
subsequent use in the IMS for the
metallation of CcO and Sod1.
MATERIALS AND METHODS
Yeast strains, culture conditions and
standard methods-  Yeast strains used in
this study were BY4741 (MATa,
leu2∆0, met15∆0, ura3∆0, his3∆1) and
the isogenic ctr1∆::kanMX4 mutant
from Research Genetics (Huntsville,
AL). sod1Δ KS107 (Mat α, leu 2-3, 112,
his3∆1, trp-289a, ura3-52,
sod1∆::TRP1) was a gift from Dr. V. C.
Culotta.  All cultures were grown in
synthetic defined media with selective
amino acids excluded with appropriate
filter sterilized carbon source added.
Metal concentration were varied by
using Bio101 yeast nitrogen base (Q-Bio
Gene) plus added 0.1 mM ferrous
chloride to give copper deficient
conditions. If required, further copper
chelation was achieved by adding filter-
sterilized copper chelator bathocuproine
sulfonate (BCS). Exogenous copper was
provided by adding CuSO4 at final
concentrations stated. All growth tests
were performed at 30oC with 1 in 10
serial dilutions of pre-cultures grown
under permissive conditions (e.g.
fermentable carbon sources or anaerobic
conditions). Anaerobic cultures were
prepared in anaerobic jars using BBL
GasPak Pd catalysts (Becton, Dickinson
and Company, USA).
Vector Constructs- Matrix-targeted
human SOD1 was described previously
(14).  Matrix-targeted CRS5 was
constructed by adding the coding
sequence for the 26 N-terminal amino
acids of Sod2 (YHR008C) in-frame to
the ORF YOR031W by overlap PCR. A
3Myc tag was added to the C-terminus by
primer extension. A stop codon present
in template genomic DNA (BY4741
background) was corrected to a serine as
per previously reported sequence (16)
using QuikChange (Stratagene). The
fusion sequence construct was cloned
into YEp vector with a heterologous
MET25 promoter sequence (300 bp
upstream of YLR303W) and a CYC1
terminator.  IM-hSOD1 was constructed
by inserting the hSod1 ORF in-frame
with the sequence encoding the N-
terminal 104 residues of Sco2
(YBR024W) that encode a targeting
sequence and a transmembrane domain
described previously (15). The promoter
element was derived from the 200 bp
upstream of SCO1 (YBR037C). All
constructs were verified by




were prepared as described previously
(14).  The soluble contents were
fractionated as described previously
(22). Anionic fractions for reverse phase
(RP) HPLC were prepared as above or
by adding DEAE (Whatman) resin in
batch. The resin was washed with 25 bed
volumes of 20 mM ammonium-acetate
pH 8.0, and eluted with 5 volumes of 1M
ammonium-acetate, pH 8.0. The samples
were loaded directly onto a Beckman
C18 resin. Unbound fractions were
removed with 50 mM ammonium
acetate pH 5.0  (or 0.1% TFA to isolate
the apo ligand). A 60 min gradient to
100% acetonitrile was used with 1 mL
fraction collected. The final fractions
were analyzed for copper by flame
atomic absorption (Perkin Elmer
AAnlyst 100) and for fluorescence in a
LB 50 fluorimeter (Perkin Elmer).
Excitation and emission scans of copper
containing fractions revealed an
excitation maximum of 220 nm and
emission maximum of 360 nm.
Excitation and emission slits of 5 nm
were used.
Mouse - Livers from mice were
recovered and mitochondria were
isolated by mechanical disruption of the
tissues by a Potter-Elvehjem
homogenizer and differential
centrifugation in 0.25 M sucrose
followed by gradient purification using a
discontinuous 22% over 28% Nycodenz
gradient. Integrity and purity were
assessed by immunoblotting and
enzymatic activity of marker proteins.
Miscellaneous methods - The
monoclonal anti-human SOD1 and
polyclonal anti-ANT1 and anti-LAMP3
were purchased from Santa Cruz. Yeast
Sod1 antisera was a gift from Dr. V.C.
Culotta.  Antisera to Por1 (porin) and
Pgk1 (phosphoglycerol kinase) were
from Molecular Probes. Enzyme assays
were preformed as described previously
(17).  Heme was extracted by the
pyridine hemochromogen method (18).
RESULTS
Human Sod1 can be activated
when targeted to the mitochondrial
matrix to complement the oxygen-
dependent phenotypes of a sod2Δ yeast
strain (14). Here we have tested whether
expression of matrix-targeted human
SOD1 (m-hSOD1) (the matrix targeting
sequence of yeast Sod2 was used) has
physiological consequences for copper-
dependent activities within the
mitochondria when compared to cells
expressing human SOD1 lacking the
matrix-targeting signal (c-hSOD1). Cells
lacking Ctr1 were used in these studies
as they have diminished copper levels
within the cell creating favorable
4conditions for the competition
experiments. Immunoblotting of ctr1Δ
transformants demonstrated the presence
of the hSod1 proteins in the predicted
compartments (Fig. 1A). Both
transformants grew equivalently in
glucose-containing medium, but the
matrix-targeted hSod1 cells were
compromised for growth on non-
fermentable carbon sources as a result of
specific loss of CcO activity (Fig. 1B
and data not shown). Respiration-
dependent growth was restored by the
addition of CuSO4 to the growth medium
(Fig. 1B), this correlated with the partial
return of CcO activity (data not shown).
The inhibited glycerol growth of
m-hSod1 containing cells may arise
from hSod1 competition with the matrix
CuL complex resulting in decreased
availability of copper for the metallation
of downstream targets. In fact a
catalytically inactive hSod1 containing
an R143A substitution was able to exert
the same dominant negative phenotype
in ctr1Δ cells (data not shown).
Mitochondrial lysates fractionated by
anion exchange chromatography
revealed that cells containing m-hSod1
had a diminished level of the matrix CuL
complex (fractions 8,9) when compared
to mitochondria from control cells with
an empty vector (data not shown) or c-
hSod1-containing cells (Fig. 1C). An
enriched copper fraction now appeared
in the column wash fractions (fraction 1-
2) that contained m-hSod1 (Fig. 1C
inset). Gel filtration chromatography of
the wash fractions (Fig. 1D) showed that
fractions containing m-hSod1 also
contained copper confirming copper
binding by m-hSod1.
 To assess the specificity of the
m-hSod1 competition for matrix copper,
a second copper-binding protein was
used. The mitochondrial targeting
sequence of Sod2 was fused to the
cytoplasmic Crs5 copper-
metallothionein to generate a matrix-
targeted variant (m-Crs5).
Immunoblotting showed that the Myc-
tagged m-Crs5 was localized in the
mitochondrion (Fig. 2A). The presence
of Crs5 within the mitochondrial matrix
did not impair the growth of yeast on
glucose medium (Fig. 2B). However, m-
Crs5 compromised growth on glycerol
medium, but this inhibitory effect was
reversed by the addition of CuSO4 to the
growth medium (Fig. 2B). Consistent
with this phenotype, CcO activity was
impaired in m-Crs5 cells, and the
supplementation of CuSO4 to the growth
medium restored its activity to a level
sufficient to support growth on a non-
fermentable carbon source (Fig. 2C). In
addition to attenuating CcO activity, the
presence of m-Crs5 led to a diminution
in the yeast Sod1 protein level within the
IMS (Fig. 2D), whereas cytosolic Sod1
was unaffected (data not shown). Sod1
protein level was restored when CuSO4
was added to m-Crs5 cell cultures (Fig.
2D).
The negative effect of matrix
Crs5 on IMS Sod1 protein levels was
further investigated by engineering a
yeast strain containing an IM-tethered
hSod1 (via the Sco2 transmembrane
domain). Cells lacking endogenous Sod1
were transformed with a vector
expressing the IM-hSOD1 fusion gene.
Immunoblotting analysis showed that the
fusion protein was intact and exclusively
localized in the mitochondrion (Fig. 3A).
The IM-hSod1 chimera reversed the
oxygen-dependent growth defect and
methionine and lysine auxotrophies of
sod1Δ cells (19) (Fig. 3B). The effect of
matrix-targeted Crs5 on IM-hSod1
activity was assessed. The presence of
m-Crs5 imparted methionine and lysine
5auxotrophies in IM-hSod1-containing
cells (Fig. 4A). Both strains grew
equivalently in the absence of oxygen.
The presence of m-Crs5 reduced the
CcO activity (data not shown) and also
attenuated the level of the IM-hSod1
chimeric protein (Fig. 4B). Increasing
the quantity of CuSO4 in the growth
medium significantly reversed the
inhibitory effect of m-Crs5 on normoxic
growth and CcO activity, but failed to
restore the steady state level of IM-
hSod1. When IM-hSod1 was expressed
from the minimal MAC1 promoter,
protein levels detected by
immunoblotting were comparable to
those shown in Fig. 4B in cells
expressing m-Crs5. This level of
expression was sufficient to complement
the methionine and lysine auxotrophies
(data not shown). Thus, the growth
defect observed with m-Crs5 was due to
a failure to activate hSod1 and not to
decreased levels of IM-hSod1.
 Characterization studies were
conducted to identify molecular
signatures of the matrix CuL complex to
enable its quantification. The matrix
CuL complex is anionic and low
molecular weight (14). Anion exchange
fractions of mitochondrial extracts
containing the CuL complex were
fractionated by reverse-phase HPLC at
pH 5 using an acetonitrile gradient (0-
100%). A single copper component
eluted at 60% of the linear gradient (Fig.
5A). Since aqueous copper is not
retained on RP-HPLC, the copper
component is ligand bound. The HPLC
purified CuL complex was subjected to
spectroscopic analysis and was found to
fluoresce with excitation and emission
maxima at 220 and 360 nm, respectively
(Fig. 5B). The quantum yield was
enhanced by the addition of potassium
cyanide that effectively removes copper
from the complex (Fig. 5B).
Fluorescence analysis of the HPLC
elution fractions revealed a co-
fractionation of the 360 nm emission
property and copper (Fig. 5A). Upon
addition of KCN and re-fractionation by
RP-HPLC, the ligand was recovered in a
similar column fraction now devoid of
copper (data not shown). The emission
of the Cu-free ligand was quenched by
the addition of Cu(I) but not by Zn(II) or
Fe(II) (Fig. 5C). In addition the levels of
the anionic fluorescent complex
recovered from mitochondrial extracts
was increased in cells grown in high
exogenous copper that result in
increased mitochondrial copper (Fig.
5D). Thus, the anionic ligand
concentration correlates with the total
mitochondrial copper.
The fluorescence property of the
matrix CuL ligand was used to quantify
the ligand in mitochondria of ctr1Δ cells
containing either c-hSod1 or m-hSod1.
Clarified mitochondrial lysate from c-
hSod1- or m-hSod1-containing cells
were adsorbed to an anion exchanger
and the total anionic fraction was
subsequently applied to reverse phase
HPLC at pH 5 (Fig. 5E). Total ligand
fluorescence (assessed after cyanide
addition) was attenuated in m-hSod1-
containing cells. Likewise,
mitochondrial ligand fluorescence was
attenuated in m-Crs5-containing cells
(Fig. 5F). The decreased yield of this
fluorescence strongly suggested that this
signature of the CuL complex is
associated with the source of Cu(I) for
CcO and Sod1 metallation within the
IMS. The presence of the competitor
proteins altered the distribution of the
matrix copper without affecting the total
mitochondrial copper content.
The fluorescent and
chromatographic properties of the ligand
6allowed us to address whether the ligand
existed in the cytoplasm. The cytosol
was fractionated into anionic and
uncharged/cationic pools by adsorption
on anion exchanger. Anionic
components were eluted in a high salt
wash of the resin. The column wash and
salt eluate were boiled to coagulate
proteins. This treatment does not alter
the concentration or the chromatographic
characteristics of the matrix CuL
complex. The clarified fractions were
chromatographed by RP-HPLC.
Fractions with retention times equivalent
to that of the mitochondrial CuL
complex were quantified by fluorimetry.
The anion exchange salt elution (anionic
fraction) contained low levels of the
fluorescent adduct, whereas the anion
exchange wash showed an abundance of
the fluorescent species (Fig. 6A). After
treatment with cyanide, this non-anionic
fraction appeared to have a quantum
yield per cell of nearly eight times over
that purified from isolated mitochondria
(Fig. 6B). While we cannot eliminate the
possibility that at least some of this
molecule was liberated from
mitochondria by our extraction
procedure, the large amount found in
these fractions suggests that the ligand is
present in the cytoplasm.
The Cu-free molecule present in
the cytoplasm could be converted to an
anionic Cu adduct by incubation with
Cu(I) and DTT (Fig. 6C). The Cu-
reconstituted adduct chromatographed
equivalently to the anionic CuL complex
on reverse phase HPLC. Quantitation of
the ligand based on fluorescence
revealed that of the total cytoplasmic
ligand only around 10% is copper bound
(Fig. 6A). Conversely, the ligand found
associated with mitochondria is >60% in
the anionic Cu-bound form (Fig. 6D).
The coordination of copper appears to
impart a net negative charge to the
complex.
To investigate the conservation
of the CuL complex in higher eukaryotes
we isolated intact pure mitochondria
from mouse liver. The purity of
mitochondria was established by western
blot analysis and marker enzyme
activities (Fig. 7A and not shown). Pure
mitochondria were analyzed for total
copper content and for heme a+a3 (Fig.
7B). As heme a+a3 is only found in
active CcO, the heme a+a3 content can
be used to quantify the levels of copper
in CcO. The analysis revealed that a
range of 10-40% of the copper present in
different mitochondrial preparations was
associated with active CcO. The mice
used in these studies were not matched
for age or sex and were from two genetic
backgrounds (contributing to the broad
range). Therefore as in yeast, CcO does
not account for the predominant pool of
copper in mouse liver mitochondria.
Soluble mitochondrial extracts
were fractionated on anion exchange
resin as we had done for yeast
mitochondria. The major copper peak
was isolated as an anionic complex that
was not sensitive to proteases
(proteinase K and trypsin) (Fig. 7C).
Further fractionation on reverse phase
chromatography revealed an identical
elution position to the yeast CuL
complex (Fig. 7D). The final fraction
had the CuL complex fluorescence and
the quantum yield was increased by
cyanide and quenched by Cu(I), but not
by Fe(II) or Zn(II) (Fig. 7E).  As in
yeast, the ligand from this complex
could be isolated in an uncharged state
in the cytosol fractions from mouse liver
(data not shown). Taken together these
data show that the CuL complex is
conserved in higher eukaryotes.
7DISCUSSION
A matrix CuL complex
conserved in the mitochondrion of yeast
and mouse liver is shown to be the
source of copper for the metallation of
CcO and Sod1. In yeast 85% and mouse
liver ~70% of the total mitochondrial
copper is associated with this matrix Cu-
complex. Targeting two different Cu-
binding proteins, human Sod1 and Crs5,
to the mitochondrial matrix but not the
cytoplasm, results in growth impairment
on non-fermentable carbon sources due
to decreased levels of CcO activity. This
effect is reversed by supplementation of
CuSO4 to the culture medium. In
addition the presence of the matrix
targeted Crs5 results in diminished Sod1
protein levels within the IMS and
impaired activity of an IM-tethered
hSod1. This tethered molecule provided
a direct marker of IMS copper. Copper
binding by the matrix-targeted proteins
attenuates the level of the anionic CuL
complex within the matrix without
affecting the total mitochondrial copper
levels suggesting that biochemical
attenuation of the matrix CuL complex
via heterologous competitor molecules
limits the available copper for
redistribution to the IMS for metallation
of CcO and Sod1.
Supplementation of cells with
exogenous copper leads to an expansion
of the matrix Cu(I) pool resulting in an
increase in the fluorescent CuL complex
(14). Under these conditions, expression
of m-hSod1 had a diminished effect on
the quantity of the CuL complex.
Therefore, the copper reversal of the
observed glycerol growth impairment in
cells harboring the matrix-targeted
proteins likely occurs from the
restoration of the matrix CuL pool. The
anionic CuL complex is fluorescent and
the fluorescence correlates with its
copper-binding status. The ligand
fluorescence provides a spectroscopic
signature that we have used for its
quantitation and identification of its
presence in the cell cytoplasm.  Attempts
to identify the ligand using different
techniques including MALDI,
electrospray and LC mass spectrometry
are ongoing. A kinetically labile copper
pool within the mitochondria, but not the
cytoplasm, was recently confirmed by
microprobe x-ray absorption
spectroscopy (20).
The ligand is found in the yeast
cytoplasm in a largely copper-free state.
The cytoplasmic ligand fails to adsorb to
an anion exchanger unless it is charged
in vitro with Cu(I). Cu(I) binding yields
an anionic complex that co-fractionates
with the matrix Cu(I) complex on RP-
HPLC. We postulate that Cu(I) binding
to the ligand within the cytoplasm
triggers the translocation of the complex
to the mitochondrion for storage and
subsequent use in CcO and Sod1
metallation within the IMS. The facile
expansion of the matrix Cu(I) pool upon
supplementation of cells with exogenous
copper is consistent with this model and
with the high concentration of apo-
ligand within the cytoplasm. The model
predicts that two types of transporters
exist within the mitochondrion. One
transporter may function in the
translocation of the CuL complex to the
matrix compartment and the second
transporter is postulated to deliver either
Cu(I) or the CuL complex to the IMS for
use by Cox17 and Ccs1 for metallation
of downstream targets. We are
developing genetic strategies to identify
the putative transporters. Considering
that the ligand is conserved in
8mammalian cells, we predict that similar
transporters exist in mammalian cells.
The apparent small
molecule/metabolite characteristic of the
copper ligand described here would be
consistent with transport across the
mitochondrial inner membrane by the
mitochondrial carrier family. This family
of 30 proteins has been shown to
transport a number of metabolites such a
S-adenosyl methionine and thiamine
pyrophosphate (21,22). Metal links exist
with this family, Mrs3 and Mrs4 are
involved in Fe transport for the assembly
of Fe-S cluster and heme and Mtm1 has
been shown to be involved in Mn/ Fe
homeostasis (23-25). The lack of non-
fermentable growth phenotypes for other
MCF deletion strains suggests that if the
putative Cu-transporter required for CcO
assembly is a MCF, it may have
redundant partners. In the case of yeast
Mrs3/4 the iron related phenotypes are
much more pronounced in the double
deletion strain (26). 
The Cu(I) ligand model for
copper transport to the mitochondrion,
eubacterial in origin, resembles a
siderophore strategy of metal ion
acquisition by bacteria. Methanotrophic
bacteria utilize a Cu-requiring membrane
methane monooxygenase in methane
catabolism and synthesize the only
characterized copper siderophore-like
complex, methanobactin. Methanobactin
is extruded by methanotrophs into the
growth medium when cells are cultured
under copper-limiting conditions and is
rapidly internalized when copper is
provided (27).  Methanobactin co-
purifies with the particulate methane
monooxygenase suggesting that Cu(I)-
methanobactin provides copper for the
catalytic function of the enzyme.
Methanobactin is a small cyclic peptide
with two chelating 4-thionyl-5-
hydroxyimidazolates that stably binds
Cu(I). Similar to the matrix CuL, the
fluorescence of methanobactin is
quenched by Cu(I). No compelling
evidence exists whether the matrix Cu(I)
ligand structurally resembles
methanobactin. The methanobactin
pathway represents a paradigm for how
mitochondrial copper acquisition may
proceed.
Finally, a number of isolated
CcO deficiencies and pleiotrophic loss
of respiratory competence with unknown
mutations have been found. As our
knowledge of the protein mediated
assembly and the complex translation
and post-translational mechanisms
controlling CcO expands, a number of
new targets for these mutations will be
identified. Unexplained CcO
deficiencies in humans may arise from
mutations in one of the proposed
transporters or mutations that affect the
ligand biosynthesis.  Importantly, the
matrix ligand maintains the cuprous state
of copper restricting its potential for
generating redox-related damage of
mitochondrial components like the
mitochondrial DNA. The ability to limit
the redox-reactivity may play a role in
normal physiology but may also be
important in the mitochondrial
dysfunction in metal-associated
neurodegenerative disorders such ALS
and Alzheimer’s disease.
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Figure legends
Fig. 1.  Human Sod1 targeted to the mitochondrial matrix has a dominant negative effect
on non-fermentable growth. A) Steady-state levels and localization of human Sod1
(hSod1). Mitochondria (M) and cytoplasmic (C) extracts were prepared from ctr1Δ cells
expressing the mitochondrial matrix-targeted hSod1 (m-hSOD1) or the cytoplasmic
hSod1 (c-hSOD1). Immunoblotting was with anti-hSod1, anti-Por1 (mitochondrial
marker) and anti-Pgk1 (cytoplasmic marker). B) Cells containing high copy vector with
m-hSOD1 or c-hSOD1 from the SOD2 promoter were plated at serial dilutions on
different carbon sources (2% glucose (top) or 2% glycerol-lactate (middle) or 2%
glycerol-lactate plus 0.5 mM CuSO4 added (bottom)). C) Anion exchange profile of
soluble extracts from mitochondria of ctr1Δ c-hSOD1 (cytoplasmic) or ctr1Δ m-hSOD1
(mitochondrial) monitoring total copper in each fraction. The copper profile (fractions 1-
20) is displayed for m-hSod1 (solid line) and c-hSod1 (dashed line). The inset is an
immunoblot to identify the elution position of hSod1. D) Fractions containing m-hSod1
(or equivalent control from c-hSod1 profile) were separated by size-exclusion
chromatography. m-hSod1 was isolated in fractions 10-11 (inset immunoblot) with
copper bound (solid line). The equivalent fractions from the c-hSod1 profile showed no
copper (dashed line) or hSod1 protein (data not shown). Copper is present in fraction 17,
the position that the Cu-complex normally elutes (data not shown) representing a fraction
that failed to absorb to the anion exchange column.
Fig. 2. Mitochondrial matrix-targeted Crs5 inhibits non-fermentable growth and causes a
decrease in the steady-state levels of IMS localized Sod1. A) Immunoblotting of the
mitochondrial (M) and cytoplasmic (C) fractions of ctr1Δ cells containing a high copy m-
CRS5. B) Growth assay of ctr1Δ cells containing either empty high copy vector (vec) or
with m-CRS5 plated at serial dilutions on different carbon sources (2% glucose (top), 2%
glycerol-lactate (middle) or 2% glycerol-lactate plus 0.5 mM CuSO4 added (bottom)). C)
Isolated mitochondria from ctr1Δ or ctr1Δ m-CRS5 yeast cells were assayed for CcO
activity. D) Immunoblot of isolated mitochondria for the endogenous steady state levels
of IMS Sod1.
Fig. 3. Human Sod1 tethered to the inner membrane is fully functional to complement the
oxidative stress phenotypes of sod1Δ yeast cells. A) Immunoblot of cytoplasm (C) and
mitochondria (M) fractions of IM-hSod1-containing sod1Δcells. Mitochondrial extracts
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of cells expressing the matrix hSod1 were used as a control to show the increased size of
the IM-hSod1 fusion. B) Cells grown anaerobically were plated in serial dilution on 2%
glucose plates or 2% glucose lacking lysine (Lys-) and methionine (Met-) and grown at
normal atmospheric oxygen (Normoxia) or in an anaerobic jar (<0.2% oxygen) (Anoxia)
to serve as a loading control.
Fig. 4. IM-hSOD1 complementation of the lysine and methionine auxotrophies of
sod1Δ yeast cells can be modulated by the mitochondrial-matrix targeted Crs5. A)
sod1Δ cells containing the IM-hSOD1 chimera gene under the control of the SCO1
promoter and either an empty vector (vec) or the chimeric m-CRS5, were plated in serial
dilution on 2% glucose Met- Lys- plates (supplemented with 0.01 mM BCS or CuSO4 as
indicated) and grown under normoxia or in an anaerobic jar (Anoxia).  B) Steady-state
protein levels for m-Crs5 and IM-hSod1. Mitochondria from sod1Δ cells expressing IM-
hSOD1 and either an empty vector (vec) or m-CRS5 were immunoblotted to detect IM-
hSod1 and the Myc-tag corresponding to m-Crs5. Two independent mitochondrial
preparations are shown.
Fig. 5. Reverse phase purification and characterization of the CuL complex. A) Reverse
phase profile of anionic fractions. Fractions (1mL) collected throughout a linear 0-100%
acetonitrile gradient (dotted line) were analyzed for copper (bars) and fluorescence (solid
line, see panel B). Emissions at 360 nm appear to co-elute with copper. B) The Cu-
containing fraction at 60% gradient showed an emission at 360 nm when excited at 220
nm. The quantum yield of 360 nm emissions was enhanced by 1 mM KCN. C) The
ligand from the CuL complex was prepared as an apo molecule by RP-HPLC at pH 2.0
then neutralized and emission scan performed. The addition of 0.5 mg copper (+Cu), but
not by addition of 0.5 mg of iron and/or zinc (+Fe +Zn), resulted in quenching of the
emission. D) Mitochondria from wild-type cells grown with or without 1 mM CuSO4
were lyzed by sonication and the anionic component loaded to RP-HPLC and profile was
analyzed for fluorescence. Extracts from cells cultured in medium without added Cu
(dashed) versus Cu–supplemented medium (solid) are shown. These conditions result in a
6-fold increase in mitochondrial copper concentration (not shown).  E) Soluble, anionic
mitochondrial extracts (normalized to mitochondrial protein levels) prepared from ctr1Δ
m-hSOD1 or ctr1Δ c-hSOD1 were loaded to RP-HPLC and emission was scanned in all
fractions after cyanide treatment. Profiles from cells producing c-hSod1 (dashed) and m-
hSod1 (solid) are shown.  F) Soluble, anionic mitochondrial extracts were prepared from
sod1Δ yeast containing IM-hSOD1 and either an empty vector (vec) or m-CRS5 RP-
HPLC elution profiles, monitoring 360 nm emissions, for vector (dashed) or m-CRS5
(solid) are shown.
Fig. 6. Quantitation of cytoplasmic and mitochondrial forms of the fluorescent copper
ligand. A) A cytoplasmic fraction prepared from WT yeast was subjected to batch anion
exchange resin followed by RP-HPLC. All fractions were scanned for fluorescence at
360 nm. Total intensity, corrected for volumes, in fluorescent fractions from the elution
of the anion exchange resin (Anionic) or flow through (Non-anionic) is shown. B)
Relative mitochondrial and cytoplasmic ligand concentrations were determined in WT by
loading soluble extracts of purified mitochondria or cytosol onto RP-HPLC. Final
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fractions containing the fluorescent complex were analyzed. C) Cytosolic fraction was
treated with copper and dithiothreitol before reapplication to batch anion exchange resin.
The copper charged anionic and non-anionic fractions were analyzed on RP-HPLC and
total intensity at 360 nm is shown. D) Purified mitochondria from WT yeast were lysed
and soluble extracts subjected to batch anion exchange resin followed by RP-HPLC. All
fractions were scanned for fluorescence 360 nm. Total intensity of anionic or non-anionic
is shown. Error bars represent standard deviation of n>3.
Fig. 7. The copper-complex is found in mouse liver mitochondria. A) Mitochondria were
prepared from mouse livers by differential centrifugation and ultracentrifugation on a
discontinuous 22%-28% Nycodenz gradient. Immunoblotting of marker enzymes ANT1
(mitochondria) and LAMP3 (lysosome) in crude mitochondria (Cr) versus; the interface
(Int) layer (pure intact mitochondria), material that could not enter the 22% Nycodenz
layer (<22%) (predominantly lysosome and mitoplasts) and material that pelleted through
the 28% layer (>28%) (other membranes) is shown. B) Reduced minus oxidized pyridine
hemochromogen spectra of intact mitochondria. The heme a+a3 peak was assessed at 590
nm and a molar extinction coefficient of 26 mM-1cm-1 (18) was used to determine the
concentration. C) Copper profiles of soluble extracts from purified mitochondria
separated by anion exchange.  Soluble copper was eluted from the column gradient in a
single peak (-PK, solid line). The elution position was not affected by the treatment of the
soluble extracts with the proteinase K (+PK, dashed line). D) Soluble, anionic fractions
from elution of anion exchange were applied to RP-HPLC at pH 5.0. The fractions from
mouse (solid) and yeast (dashed) are shown. E) Emission scans of the fluorescent
component after removal of the copper (apo) and after the addition of 0.5 mg copper
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